Alnylam Pharmaceuticals
ALNY
#1138
Rank
C$28.37 B
Marketcap
C$211.86
Share price
-1.06%
Change (1 day)
-67.23%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): C$1.71 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$5.01 Billion. In 2025 the company made an earning of C$1.02 Billion, an increase over its 2024 earnings that were of -C$0.34 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) C$1.71 B67.22%
2025 C$1.02 B-403.41%
2024 -C$0.34 Billion-24.59%
2023 -C$0.45 Billion-67.84%
2022 -C$1.4 Billion36.93%
2021 -C$1.02 Billion-8.04%
2020 -C$1.11 Billion-15.66%
2019 -C$1.32 Billion12.23%
2018 -C$1.17 Billion62.91%
2017 -C$0.72 Billion17.78%
2016 -C$0.61 Billion43.44%
2015 -C$0.43 Billion60.69%
2014 -C$0.27 Billion98.2%
2013 -C$0.14 Billion
2011 -C$78.57 Million27.48%
2010 -C$61.63 Million-10.92%
2009 -C$69.19 Million95.77%
2008 -C$35.35 Million
2006 -C$56.62 Million-9.13%
2005 -C$62.31 Million34.74%
2004 -C$46.25 Million36.79%
2003 -C$33.81 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
C$18.12 B 935.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$11.16 B 537.61%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$8.15 B 365.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-C$0.19 Billion-110.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-C$67.98 Million-103.88%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-C$0.23 Billion-113.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.75 B 0.21%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-C$0.23 Billion-113.06%๐Ÿ‡บ๐Ÿ‡ธ USA